Trial Profile
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2019
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Advanced breast cancer; Biliary cancer; Carcinoma; Endometrial cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Head and neck cancer; Neuroendocrine tumours; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 21 Sep 2016 Status changed from recruiting to completed.
- 26 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Aug 2015 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Jun 2015 to 1 Sep 2015.